ABSTRACT
INTRODUCTION Polygenic Risk Scores for Alzheimer dementia (AD-PRS), a measure of aggregate AD genetic risk and polypharmacy have been associated with dementia. Here, we test their interaction’s association with future dementia among older adults without baseline neurodegenerative diagnoses.
METHODS Using Cox proportional hazards and mortality-adjusted competing risk regression models we analysed up to 17.5 years all-cause incident dementia in the Lothian Birth Cohort 1936 (n=759, 105 dementia patients). We used polypharmacy (total or nervous-system-acting medications count), AD-PRS, and their interaction as main predictors.
RESULTS A non-significant interaction was found between AD-PRS and total polypharmacy (HR=1.06; p=0.15) or nervous-system-acting polypharmacy (HR=0.98; p=0.86) in shaping dementia risk. Omitting interaction, mortality-adjusted models showed significant AD-PRS prediction of dementia (HR ∼1.40; p<0.001), non-significant total (HR=1.03; p=0.49), and nervous-system-acting polypharmacy effects (HR=1.27; p=0.069).
DISCUSSION Elucidating the complex interplay between polypharmacy and genetics could improve management of inappropriate medication in older adults genetically prone to dementia/AD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was funded by the Legal & General Group (research grant to establish the independent Advanced Care Research Centre at University of Edinburgh). The funder had no role in conduct of the study, interpretation or the decision to submit for publication. The views expressed are those of the authors and not necessarily those of Legal & General.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The LBC1936 study is supported by the Biotechnology and Biological Sciences Research Council (BBSRC) and the ESRC (BB/W008793/1), Age UK (Disconnected Mind project), the Milton Damerel Trust, and the University of Edinburgh. SRC was supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (221890/Z/20/Z). The Lothian Birth Cohort 1936 study acknowledges the financial support of NHS Research Scotland (NRS), through Edinburgh Clinical Research Facility.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Information about accessing LBC1936 data can be found here: https://lothian-birth-cohorts.ed.ac.uk/data-access-collaboration
